Luca Research Biotech Club (@Biobeats99) profile picture

Biotech Investors Network 🧬 | Connecting biotech investors & sharing insights. Join our group chat in Telergam https://teapawt.net/t.co/w4LGQzUe7l

London, England
Joined August 2023
Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)Photo by Luca Research Biotech Club (@Biobeats99)
$IMMX: Mizuho - NXC-201's next pivotal AL-amyloidosis update arrives Dec. 14: all 16 patients with more than 12 months of follow-up were in complete response, while the prior 45-patient update showed an 89% CR rate. Final data are due in March and a BLA in mid-2027. Durability supports the case, but a small single-arm CAR-T dataset still must clear regulatory and commercial hurdles. Peers: JNJ ABBV REGN BMY
49
$LYCA: Guggenheim - LCA-0061 reduced free and total IgE by about 96% after a single dose in atopic patients, validating Lycia's extracellular protein-degrader platform. The profile may reach severe food-allergy patients outside Xolair's weight and IgE limits and permit less frequent dosing. Full Phase 1 data arrive in 2027, so clinical durability, safety and allergy efficacy remain unproven. Peers: RHHBY REGN SNY VRTX
114
$ORIC: Cantor - Rinzimetostat plus darolutamide maintained roughly 60% radiographic PFS at 9-10 months in Phase 1 prostate-cancer cohorts, tracking near Pfizer's mevrometostat despite heavier pretreatment. Diarrhea was 24% with no grade 3 or worse events, suggesting a cleaner profile. Pfizer's MEVPRO-1 Phase 3 readout in 1Q27 is the key mechanism readthrough. Peers: PFE JNJ BMY NVS Join the discussion in Bio Talks [Link in Bio]
1
190
$NAMS: Guggenheim - A cardiology KOL sees PREVAIL as more likely to succeed than earlier CETP outcomes trials and views at least 15% relative risk reduction as highly meaningful, while even a single-digit to mid-teen effect could support use for patients avoiding injectables. Obicetrapib's A1C and kidney signals add upside, but the cardiovascular-outcomes readout must validate the mechanism. Peers: IONS ARWR AMGN NVO
6
410
$BBIO: RBC - A policy expert expects the new 340B reimbursement rule to take effect in January 2027 despite likely hospital litigation. He sees ALNY facing margin or volume pressure because Amvuttra has substantial 340B exposure, while alternatives such as Attruby may gain. The rule remains legally contestable, so the competitive readthrough for BridgeBio is favorable but not settled. Peers: ALNY PFE NVS VRTX
1
2
400
$ACRS: Cantor - Bosakitug TSLP monotherapy failed in Phase 2 atopic dermatitis, reinforcing prior class failures and making development of the TSLP/IL-4R bispecific in AD unlikely. Cantor sees capital shifting toward eosinophilic esophagitis as constructive. The thesis now rests more heavily on modzatinib in lichen planus, where Phase 2b topline is expected in 2H27. Peers: REGN SNY AZN ZBIO
186
$LLY: Citi - Lilly is acquiring private Calytrix Bio for up to USD 1.5B to add a preclinical biparatopic antibody targeting the two major mutant-CALR variants in myelofibrosis and essential thrombocythemia. The asset could complement Lilly's Phase 1 JAK2 inhibitor by attacking the disease-driving clone, but the upfront is undisclosed and efficacy and safety remain wholly untested in humans. Peers: INCY KURA CTBI BMY
163
$CYTK: BofA - FDA added the MAPLE head-to-head data to Myqorzo's label, but did not specify first-line use and said the clinical meaning of peak oxygen uptake is unclear. Symptoms improved versus metoprolol, with NYHA improvement of 51% versus 26%, yet BofA sees the wording supporting payer step edits. Launch share, pricing and the pending non-obstructive HCM filing remain the key debates. Peers: BMY BRVE EWTX TTAN
1
3
483
$LXEO: Stifel - High-dose LX2020 reduced NSVT by 80% and PVCs by 44% at 9-18 months in seven PKP2 cardiomyopathy patients, with six of seven improving on NSVT. FDA is open to accelerated approval using an NSVT endpoint, and a pivotal study may start in 2H27. The signal deepened with follow-up, but the cohort is tiny and final trial design awaits 1H27 alignment. Peers: FDMT QURE SRPT RCKT
1
463
$HELP: Jefferies - HLP003 met the Phase 3 APPROACH endpoint in adjunctive depression, producing a 7.6-point placebo-adjusted MADRS benefit at week 6 and 7.0 points at week 12. Remission was 51% versus 18% on placebo. Three drug-related serious events require detail, while the second pivotal EMBRACE readout in 4Q27 is needed before a planned 2028 NDA. Peers: CMPS ATAI CYBN GHRS Join the discussion in Bio Talks [Link in Bio]
1
3
1,033
$BHVN: Cantor - FDA accepted the troriluzole NDA resubmission for spinocerebellar ataxia, set a 1Q27 decision and plans an advisory committee. With no approved therapy, investors see scope for regulatory flexibility, but the application relies on new analyses after a prior rejection. AdCom scrutiny and the agency's treatment of other high-unmet-need filings will frame approval probability. Peers: BIIB PRAX XENE NBIX
2
3
547
$NVS: Jefferies - FDA is investigating malignancies after Zolgensma, with nine tumors reported among more than 6,000 treated patients and vector-DNA integration found in two cases. The agency says benefits still outweigh risks, but a label update and enhanced long-term monitoring are possible. The review also raises a broader safety question for AAV gene therapy. Peers: SRPT RHHBY CRSP NTLA
4
518
$BLTE: Cantor - FDA will not convene an advisory committee for tinlarebant ahead of its Feb. 12, 2027 Stargardt-disease decision, while management says the mid-cycle review is complete and a late-cycle meeting is scheduled. The regulatory process appears orderly, but the first potential therapy for this orphan retinal disease still carries approval, labeling and launch-execution risk. Peers: APLS ISEE EYPT RHHBY
1
1
7
921
$MBX: JPMorgan - Upcoming 12-week multiple-dose data will test whether once-monthly MBX-4291 can pair obesity efficacy comparable with approved agents with better gastrointestinal tolerability. JPMorgan sees monthly dosing and tolerability as the core differentiation, but the update remains an early clinical readout where placebo response, safety and durability can reset the product profile. Peers: LLY NVO GPCR AMGN
3
2
7
985
$SMMT: Jefferies - FDA rejected ivonescimab plus chemotherapy in second-line EGFR-mutant lung cancer because PFS benefit without statistically significant OS was insufficient. HARMONi showed median PFS of 6.8 versus 4.4 months, while OS narrowly missed at p=0.057. Jefferies sees limited valuation impact; HARMONi-3 first-line PFS around year-end remains the thesis-defining catalyst. Peers: MRK AZN BMY JNJ Join the discussion in Bio Talks [Link in Bio]
3
1
19
3,275
$IONS: Jefferies - An sHTG KOL says limited physician awareness and specialist referrals are bigger barriers to Tryngolza uptake than expected. Reimbursement can require lifestyle changes and conventional therapy first, creating a lag that may approach one year. The readthrough tempers near-term launch expectations and raises the importance of community education, access and high-volume prescriber targeting. Peers: ARWR ALNY NVS AMGN
3
488
$VRTX: UBS - A kidney KOL is moving IgAN patients toward APRIL or APRIL/BAFF therapy and favors longer dosing intervals, while insurance authorization still slows uptake. He has roughly 30-35 diagnosed high-risk APOL1 patients, similar to his IgAN population, supporting Vertex's commercial push. The academic-center setting may overstate testing and readiness in community practice. Peers: VERA JBIO ADRX ALNY
204
$INCY: BofA - A City of Hope KOL sees INCA033989 as a potential disease-modifying treatment and preferred option for CALR-mutated myelofibrosis and essential thrombocythemia if early spleen, symptom and molecular responses hold. She expects broad adoption in more than half of eligible MF patients, but longer follow-up must establish durability, cytopenia risk and the value of adding ruxolitinib. Peers: CTBI GSK BMY KURA
182
$PRME: Citizens - A USD 143.7M offering extends Prime Medicine's runway through 2027 and beyond initial PM577a Wilson-disease data. The first patient entered the Phase 1/2 study in October, while PM647 enrollment in AATD is underway. Prime editing now reaches clinical proof of concept, but the roughly 23% share-count increase highlights dilution and first-in-human execution risk. Peers: CRSP NTLA BEAM VERV
1
3
1,190
$NGEN: TD Cowen - FDA Breakthrough Therapy designation validates NVG-291's preliminary hand-function signal in chronic spinal-cord injury and supports the Phase 3 RESTORE strategy. CONNECT showed a 3.3-point placebo-adjusted improvement at week 12, but included only 20 patients. RESTORE is enrolling about 150 patients, with completion expected in 2H27 and topline data in 1H28. Peers: PRAX DNLI BIIB SAGE
1
3
598